Whitehawk Therapeutics presented new preclinical data for three antibody drug conjugates (ADCs)—HWK-007, HWK-016, and HWK-206—demonstrating potent tumor regression, high stability, and favorable tolerability in animal models. HWK-007 and HWK-016 are currently in Phase 1 trials targeting lung, ovarian, and endometrial cancers, while HWK-206 is on track for an IND submission and Phase 1 trial initiation in 2026. These ADCs use Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing technology to improve delivery and reduce side effects, potentially offering best-in-class treatment options for difficult cancers. The company plans to advance clinical development based on these encouraging results.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Peter Schiff, seorang kritikus Bitcoin, menyarankan investor untuk menjual kepemilikan BTC mereka di atas $60.000, memperingatkan potensi kerugian besar. Meskipun Bitcoin baru-baru ini naik 11% di bulan Juli, beberapa analis khawatir bahwa pemulihan ...
